Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
magazineBig medical breakthrough drives huge gains in Oxford Biodynamics shares
Biotechnology company Oxford Biodynamics (OBD:AIM) has seen its shares go up three-fold in the last month driven by positive news flow.
The company, which is developing precision medical tests based on its proprietary EpiSwitch3D genomics platform, announced earlier than expected validation of its prostate screening test on 26 September.
The test is groundbreaking in that it has proven to be 94% accurate in predicting the presence or absence of prostate cancer compared with 55% accuracy from current screening methods used by the NHS.
Increased accuracy of the test, which will be run alongside a standard test, significantly removes false positives and the need for unnecessary referrals and invasive biopsies.
Further exciting news came on 18 October when Oxford Biodynamics announced a strategic partnership with Bupa, the UK’s leading health insurer, to give patients access to EpiSwitch Cirt (Checkpoint inhibitor Response Test).
It is a first-of-its-kind blood test that accurately predicts an individual cancer patient’s therapeutic response to treatment and thereby identifies those most likely to benefit from this class of therapy.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
